U-M Football Event Supports Cancer Research
The University of Michigan Health System, in partnership with Michigan Athletics, is gearing up for an event that combines Michigan football and U-M's cancer research.
The Michigan Men's Football Experience runs June 6-7 and is still registering participants.
Capturing circulating cancer cells could provide insights into how disease spreads
A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.
Engineering and medical researchers at the University of Michigan have devised such a set-up, which they say takes advantage of cancer cells' stronger drive to settle and bind compared with normal blood cells.
U-M researchers develop method that could enhance gene sequencing data
When researchers sequence the RNA of cancer cells, they can compare it to normal cells and see where there is more RNA. That can help lead them to the gene or protein that might be triggering the cancer.
Gene sequencing program helps identify cancer mutations
MI-ONCOSEQ effort gives researchers new leads to improve treatments
It started with a 44-year-old woman with solitary fibrous tumor, a rare cancer seen in only a few hundred people each year.
By looking at the entire DNA from this one patient's tumor, researchers have found a genetic anomaly that provides an important clue to improving how this cancer is diagnosed and treated.
Although just out of high school, Matt Vogel left a lasting legacy for others facing rare skull base tumors
In the years since Matthew Vogel died, part of him has continued on at the University of Michigan.
A native of Kansas who was studying at St. Olaf College in Minnesota, Matt lost his life to sinonasal undifferentiated cancer, or SNUC, in 1997. But his final gift continues to provide hope for others like him, others who will get the difficult news that they have a rare and little-understood skull base tumor with a poor prognosis.
U-M study challenges notion of using Herceptin only for HER2-positive breast cancer
Breast cancer stem cells express HER2, even in 'negative' tumors, study finds
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative -- and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.
Welcome to the spring edition of the University of Michigan Comprehensive Cancer Center's electronic newsletter. I'm pleased to be able to share with you some of the interesting and exciting ways that the UMCCC continues to make great strides in understanding, diagnosing, preventing and treating cancer.